Aptamers and siRNAs in cardiovascular disease

Published

Book Section

© 2008 Springer-Verlag Berlin Heidelberg. Cardiovascular disease is the most common cause of death in the United States, and is a leading cause of morbidity. In addition, many drugs used to treat various arenas of cardiovascular disease have untoward side effects and less than desirable safety profiles. To meet the challenge of developing safe and effective treatments, aptamers and siRNAs are being developed that display promising potential. Aptamers are relatively small, synthetic nucleic acid ligands that possess high affinity and specificity for their target proteins. Also, antidote oligonucleotides may be rationally designed against any aptamer, thus introducing an additional level of safety. Similarly, siRNAs may be rationally designed to cleave any messenger RNA through sequence complimentarity, thus silencing gene expression. Also, their effects have been shown to be long lasting, reducing the need for daily treatment. Here, we present background information on both aptamer- and siRNA-based therapeutics, and in particular focus on their applications to many areas of cardiovascular disease, namely anticoagulation, intimal hyperplasia, hypertension, myocardial ischemia, atherosclerosis and heart failure. In addition, potential challenges to both fields are discussed, and ideas on how to overcome these hurdles are offered. Overall, both aptamers and siRNAs represent attractive, novel nucleic acid therapies for the prevention and treatment of cardiovascular disease.

Full Text

Duke Authors

Cited Authors

  • Blake, CM; Oney, S; Nimjee, SM; Sullenger, BA

Published Date

  • January 1, 2008

Book Title

  • RNA Technologies in Cardiovascular Medicine and Research

Start / End Page

  • 255 - 287

International Standard Book Number 13 (ISBN-13)

  • 9783540787082

Digital Object Identifier (DOI)

  • 10.1007/978-3-540-78709-9_13

Citation Source

  • Scopus